Stephen Liu: Update from phase 3 IMscin001 trial JTO and JTO CRR

Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter:

“Update from phase 3 IMscin001 trial JTO & JTO CRR. Pts with NSCLC randomized 2:1 to subcutaneous vs IV atezolizumab. Similar OS (10.7 vs 10.1m) and safety. Subcutaneous typically took 4-8 minutes; felt more convenient, with higher satisfaction scores.”

Read further.
Source: Stephen Liu/X
OncoDaily
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.